Insmed Incorporated (INSM)
NASDAQ: INSM · Real-Time Price · USD
101.49
-1.63 (-1.58%)
At close: Jul 30, 2026, 4:00 PM EDT
102.00
+0.51 (0.50%)
Pre-market: Jul 31, 2026, 4:00 AM EDT
Insmed Employees
Insmed had 1,664 employees as of December 31, 2025. The number of employees increased by 393 or 30.92% compared to the previous year.
Employees
1,664
Change (1Y)
393
Growth (1Y)
30.92%
Revenue / Employee
$492,526
Profits / Employee
-$711,391
Market Cap
22.00B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 1,664 | 393 | 30.92% |
| Dec 31, 2024 | 1,271 | 359 | 39.36% |
| Dec 31, 2023 | 912 | 176 | 23.91% |
| Dec 31, 2022 | 736 | 123 | 20.07% |
| Dec 31, 2021 | 613 | 92 | 17.66% |
| Dec 31, 2020 | 521 | 86 | 19.77% |
| Dec 31, 2019 | 435 | 62 | 16.62% |
| Dec 31, 2018 | 373 | 159 | 74.30% |
| Dec 31, 2017 | 214 | 53 | 32.92% |
| Dec 31, 2016 | 161 | 36 | 28.80% |
| Dec 31, 2015 | 125 | 36 | 40.45% |
| Dec 31, 2014 | 89 | 28 | 45.90% |
| Dec 31, 2013 | 61 | 20 | 48.78% |
| Dec 31, 2012 | 41 | -1 | -2.38% |
| Dec 31, 2011 | 42 | 2 | 5.00% |
| Dec 31, 2010 | 40 | 25 | 166.67% |
| Dec 31, 2009 | 15 | -82 | -84.54% |
| Dec 31, 2008 | 97 | 3 | 3.19% |
| Dec 31, 2007 | 94 | -63 | -40.13% |
| Dec 31, 2006 | 157 | 72 | 84.71% |
| Dec 31, 2005 | 85 | 30 | 54.55% |
| Dec 31, 2004 | 55 | 35 | 175.00% |
| Dec 31, 2003 | 20 | -3 | -13.04% |
| Dec 31, 2002 | 23 | -37 | -61.67% |
| Dec 31, 2001 | 60 | 20 | 50.00% |
| Dec 31, 2000 | 40 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| BeOne Medicines AG | 12,000 |
| BioNTech SE | 7,807 |
| Moderna | 4,700 |
| Genmab | 3,088 |
| Jazz Pharmaceuticals | 2,890 |
| Incyte | 2,844 |
| Ascendis Pharma | 1,189 |
| Exelixis | 1,077 |
INSM News
- 7 days ago - Insmed to Host Second-Quarter 2026 Financial Results Conference Call on Thursday, August 6, 2026 - PRNewsWire
- 10 days ago - Insmed initiated with an Outperform at BMO Capital - TheFly
- 14 days ago - Insmed Transcript: Study result - Transcripts
- 14 days ago - Insmed Press release: Study result - Filings
- 14 days ago - Insmed Slides: Study result - Filings
- 14 days ago - Insmed’s inhalation powder shows efficacy and safety in arterial hypertension - TheFly
- 14 days ago - Insmed Announces Positive 12-Month Data from the Ongoing Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Patients with Pulmonary Arterial Hypertension - PRNewsWire
- 15 days ago - Insmed price target raised to $161 from $160 at Wells Fargo - TheFly